Bejelentkezés Regisztrálj ingyen

Novabay Pharmaceuticals Inc Adósság / tőke

Mi az Novabay Pharmaceuticals Inc Adósság / tőke?

A Adósság / tőke az Novabay Pharmaceuticals Inc - 1.73

Mi a Adósság / tőke meghatározása?



Az adósság és a saját tőke aránya a társasági eszközök finanszírozásához használt saját tőke és adósság viszonylagos arányát jelző pénzügyi arány.

The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.

Adósság / tőke a Health Care szektor a NYSEMKT-on cégekben a Novabay Pharmaceuticals Inc -hoz képest

Mit csinál Novabay Pharmaceuticals Inc?

novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across

adósság / tőke -hoz hasonló cégek Novabay Pharmaceuticals Inc